Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis.
Close cooperation among various specialties including surgeons, oncologists, radiation oncologists, pathologists, and radiologists is extremely important for the chance of survival in patients with resectable disease and borderline resectable disease.
Pancreatic Cancer Risk Factors
Ten percent have a genetic cause such as genetic mutations or association with syndromes such as Lynch syndrome, Peutz-Jeghers syndrome, VonHipaul Lindau syndrome, MEN1 (multiple endocrine neoplasia type 1).
Possible risk factors include heavy alcohol consumption, coffee consumption, physical inactivity, high red meat consumption, and two or more soft drinks per day.
Based on the GLOBOCAN 2012 estimates, pancreatic cancer kills more than 331,000 people per year and ranks as the seventh principal cause of cancer death in both genders. The estimated global, 5-year survival rate for pancreatic cancer is about 5%.
Incidence rates for pancreatic cancer for both genders were highest in Northern America, Western Europe, Europe, and Australia/New Zealand. The lowest incidence rates are in Middle Africa and South-Central Asia.
There are some gender differences globally. In men, the greatest risk of developing pancreatic cancer is in Armenia, Czech Republic, Slovakia, Hungary, Japan, and Lithuania. The lowest risk for men is in Pakistan and Guinea. In women, the highest incidence rates are in Northern America, Western Europe, Northern Europe and Australia/New Zealand. The lowest rates for women are in Middle Africa and Polynesia.
The incidence rates for both genders increase with age; the highest is older than 70 years. Approximately 90% of all cases of pancreatic cancer are among people over 55 years of age.
Pancreatic cancer can be of adenocarcinoma origin, serous, seromucinous, or mucinous.
More than 90% of adenocarcinoma of the pancreas are duct cell adenocarcinomas with other types being cystadenocarcinoma and acinar cell carcinoma. Two-thirds arise in the pancreatic head; one-third arise in the rest (body and tail of pancreas). Several research articles have evaluated the genetic nature of various subtypes of pancreatic cancer, providing an overall genetic makeup of pancreatic cancer. These genetic patterns can later be used to create targeted therapy, potentially improving survival in pancreatic cancer patients.
Tumor markers associated with pancreatic cancer include CEA and CA 19-9.
Patients with adenocarcinoma of pancreas typically present with painless jaundice (70%) usually due to obstruction of the common bile duct from the pancreatic head tumor. Weight loss occurs in about 90% of patients. Abdominal pain occurs in about 75% of patients. Weakness, pruritus from bile salts in the skin, anorexia, palpable, non-tender, distended gallbladder, acholic stools, and dark urine. Sometimes, patients may present with recurrent deep vein thrombosis (DVT) due to hypercoagulability that prompts clinicians to suspect cancer and a full workup of cancer.
Patients can also present with recent-onset diabetes.
Lab findings will include elevation in liver function tests, direct and total bilirubin levels, elevated amylase and lipase, and elevated pancreatic tumor markers (CA 19-9 and CEA).
If adenocarcinoma of the pancreas is suspected, multidetector computed tomography, MDCT, is the best imaging modality to diagnose and evaluate the extent of disease including perivascular extension and distant metastasis. MDCT is 77% accurate in predicting resectability and 93% accurate in predicting unresectability.
Multidetector CT protocol for pancreatic imaging utilizes a multiphase imaging technique, which includes a late arterial phase and a portal venous phase after administration of intravenous contrast material. The late arterial or pancreatic phase is acquired at 35 to 50 seconds after the injection and allows optimum evaluation of the pancreatic parenchyma. The portal venous phase is acquired at 60 to 90 seconds after the injection of intravenous (IV) contrast and allows for optimum assessment of the venous anatomy and is best for the detection of hepatic and distant metastatic disease. Water can be used as oral contrast. Barium-based oral contrast is generally not used, as it will interfere with the evaluation of vascular anatomy and encasement. Multiplanar reformatted images in the coronal and sagittal plane, maximum intensity projection images, and volume-rendered images are helpful to delineate vascular encasement and narrowing better.
PET CT scan can be useful in detecting distant metastatic disease.
Abdominal MRI /MRCP with IV contrast is as good in the preoperative evaluation of pancreatic cancer and the assessment of vascular invasion. MRI is more sensitive to detect metastatic hepatic disease with a sensitivity approaching 100% as compared with 80% for CT. MRI also employs a standard multiphase post contrast imaging protocol. There is a small subset of pancreatic adenocarcinoma which will provide the same attenuation on CT scan so that it will be more conspicuous on MRI. If pancreatic cancer is highly suspected and the CT scan is negative, that would be an indication to order further imaging with MRI of the abdomen with IV contrast. The downside to MRI is that if the patient cannot follow breathing instructions or has difficulty holding their breath, the images will be of poor quality. CT images are much faster to obtain and do not require significant breath hold ability.
Ultrasound is of limited value in pancreatic imaging. Often the pancreas will be poorly visualized sonographically secondary to bowel gas. Ultrasound can detect the secondary biliary ductal dilatation associated with pancreatic head cancer but it not so useful in visualizing the pancreatic mass itself.
ERCP with endoscopic ultrasound can be performed, and fine needle aspiration biopsies can be done of suspicious lesions for the pathologic specimen. However, with a mass in the pancreas, biopsy confirmation is not necessary, and one can proceed directly to excision given that full workup has been performed.
Endoscopic ultrasound, a test performed by gastroenterologists, can delineate the pancreatic mass and can be used to biopsy the mass under ultrasound guidance.
Endoscopic retrograde cholangiopancreatography (ERCP) is a test in which a contrast dye is injected into the biliary ducts and pancreatic duct with an endoscope. The level of biliary or pancreatic obstruction can be delineated. In some case, placement of a biliary stent can help relieve symptoms of jaundice.
If the pancreatic adenocarcinoma is considered locally advanced then by definition it is unresectable. Neoadjuvant treatment with chemotherapy and/or radiation is typically perferred in this situation. Treatment with chemotherapy takes approximately
If the adenocarcinoma of the pancreas is located in the head of the pancreas, then the Whipple procedure (pancreaticoduodenectomy) is the procedure of choice. If the tumor is in the body or tail of the pancreas, the distal resection is needed. Postoperatively, patients may receive chemotherapy with 5-FU, gemcitabine, and radiotherapy. If the hepatic artery is involved in the tumor, then the tumor is considered to be unresectable. However, if the superior mesenteric vein is involved in the tumor, then resection and vascular reconstruction. The same is true for portal vein involvement. It can be resected and reconstructed with graft.
If the adenocarcinoma of the pancreas is located in the body or tail of the pancreas, then the surgical procedure of choice is distal pancreatectomy with splenecotmy. If there is extensive involvement of the celiac artery and splenic artery, then a modified Appleby procedure can be performed if meets criteria .
Minimally invasive approaches to Whipple and distal pancreatectomy with splenectomy have been investigated with similar outcomes in survival and morbidity and mortality .
Typically, at the time of diagnosis of pancreatic cancer, 52% have distant metastasis, and 23% have local spread.
Differential diagnosis before imaging and biopsy includes the following: acute pancreatitis, chronic pancreatitis, cholangitis, cholecystitis, choledochal cyst, peptic ulcer disease, cholangiocarcinoma, and gastric cancer.
Neoadjuvant first approach in resectable pancreatic adenocarcinoma is implemented more and more frequently at high-volume centers nationwide and internationally. The rational behind neoadjuvant first approach is that the patient is in their best shape to receive chemotherapy and at best odds of completing chemotherapy for 4-6 months. In addition, tissue is thought to be still well-oxygenated having not gone through a large procedure such as the Whipple. Many patients do not complete or even start adjuvant chemotherapy after surgical resection, thereby decreasing their survival. 
SWOG 1501 Trial recently evaluated neoadjuvant treatment first approach in resectable pancreatic cancer with disappointing results. Only approximately 73% went on to have resection. Survival rates were comparable to those of adjuvant trials .
There is a role for radiation therapy in combination with chemotherapy to treat locally advanced pancreatic cancer. Radiation therapy was originally used to alleviate the pain, but its use is currently becoming more widespread to shrink tumors and increase survival.
Most patients that are deemed possibly resectable for pancreatic cancer should receive neoadjuvant chemotherapy. The two main regimens used are FOLFIRINOX and gemcitabine plus protein-bound paclitaxel . Many patients who are younger, fit, and have minimal comorbidities are offered FOLFIRINOX (a combination of 5-fluorouracil, oxaliplatin, and irinotecan). This regiment is extremely toxic and only fit, young patients can withstand it. For patients who are older and/or not as healthy might be offered gemcitabine and protein-bound paclitaxel. Protein-bound paclitaxel is a taxane that is an albumin conjugate and has a lower risk profile than FOLFIRINOX. Of note, these two regimens were initially used for postoperative use. Now, however, these regiments are considered before and after surgery. The typical duration of each regimen is 4 to 6 months .
Pain management is extremely important. Pancreatic cancer is one of the most painful malignancies. Opioids, antiepileptics, and corticosteroids all are effective for pain relief.
Stage I: Tumor is located in the pancreas and does not extend elsewhere
Stage II: Tumor infiltrates bile duct and other near structures, however lymph nodes are negative
Stage III: Any positive lymph nodes
Stage IVA: Metastases into nearby organs such as stomach, liver, diaphragm, adrenals
Stage IVB: Tumor infiltrates distant organs
Inoperability is signified on imaging by superior mesenteric artery encasement, liver metastases, peritoneal implants, distal lymph node metastases, and distant metastases.
Prognosis for pancreatic adenocarcinoma remains poor despite advances in cancer therapy. The 5-year survival rate is approximately 20%. Prognosis after 1 year of diagnosis is dismal, with 90% of patients dying at 1 year despite surgery. However, palliative surgery can be of benefit.
Postoperative complications of pancreatic surgery include pancreatic fistulas, delayed gastric emptying, anastomotic leaks, bleeding, and infection.
For patients with metastatic, stage IV, pancreatic cancer, discussions with the patient regarding treatment are essential. One can receive chemotherapy. However, the life prolongation will be at best months, yet affected the toxicity and effects of the chemotherapy. It is important to keep nutrition on the forefront of the patient's care as nutrition can affect wound healing.
Palliative and/or supportive care, hospice, dietary, nutrition, physical therapy, occupational therapy
It is important to discuss with the patient all the treatment options before discussing surgery.
Delayed gastric emptying is a common complication of Whipple procedure. Similarly, anastomotic leaks pose significant morbidity to the patient.
The diagnosis and management of pancreatic cancer is with an interprofessional team that consists of an oncologist, general surgeon, radiologist, pain specialist, gastroenterologist, palliative care nurse, and an internist. By far the majority of cases of pancreatic cancer are advanced at the time of presentation and these patients have a very short life expectancy. Palliative care and a pain specialist should be involved in the care of these patients. Coordination of education of the family by the palliative nurse or provider is key because survival is severely reduced in most patients. The surgery for pancreatic cancer is complex and technically demanding. Even those who undergo successful resection may develop serious life-threatening complications which may alter the quality of life.  (Level V)
|||Kanno A,Masamune A,Hanada K,Kikuyama M,Kitano M, Advances in Early Detection of Pancreatic Cancer. Diagnostics (Basel, Switzerland). 2019 Feb 5; [PubMed PMID: 30764550]|
|||Betés M,González Vázquez S,Bojórquez A,Lozano MD,Echeveste JI,García Albarrán L,Muñoz Navas M,Súbtil JC, Metastatic tumors in the pancreas: the role of endoscopic ultrasound-guided fine-needle aspiration. Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva. 2019 Feb 11; [PubMed PMID: 30746956]|
|||De Luca L,Repici A,Koçollari A,Auriemma F,Bianchetti M,Mangiavillano B, Pancreatoscopy: An update. World journal of gastrointestinal endoscopy. 2019 Jan 16; [PubMed PMID: 30705729]|
|||Bausch D,Keck T, Minimally Invasive Surgery of Pancreatic Cancer: Feasibility and Rationale. Visceral medicine. 2018 Dec; [PubMed PMID: 30675490]|
|||Vaziri-Gohar A,Zarei M,Brody JR,Winter JM, Metabolic Dependencies in Pancreatic Cancer. Frontiers in oncology. 2018; [PubMed PMID: 30631752]|
|||Kleinerman RA,Tucker MA,Sigel BS,Abramson DH,Seddon JM,Morton LM, Patterns of Cause-Specific Mortality Among 2053 Survivors of Retinoblastoma, 1914-2016. Journal of the National Cancer Institute. 2019 Jan 30; [PubMed PMID: 30698734]|
|||Kurahara H,Shinchi H,Ohtsuka T,Miyasaka Y,Matsunaga T,Noshiro H,Adachi T,Eguchi S,Imamura N,Nanashima A,Sakamoto K,Nagano H,Ohta M,Inomata M,Chikamoto A,Baba H,Watanabe Y,Nishihara K,Yasunaga M,Okuda K,Natsugoe S,Nakamura M, Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Langenbeck's archives of surgery. 2019 Jan 16; [PubMed PMID: 30649607]|
|||Lee DH,Jang JY,Kang JS,Kim JR,Han Y,Kim E,Kwon W,Kim SW, Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data. Annals of hepato-biliary-pancreatic surgery. 2018 Nov; [PubMed PMID: 30588531]|
|||Amodeo S,Masi A,Melis M,Ryan T,Hochster HS,Cohen DJ,Chandra A,Pachter HL,Newman E, Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. Journal of gastrointestinal oncology. 2018 Oct; [PubMed PMID: 30505595]|
|||Colombo PE,Quenet F,Alric P,Mourregot A,Neron M,Portales F,Rouanet P,Carrier G, Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy. Annals of surgical oncology. 2020 Jun 25; [PubMed PMID: 32588265]|
|||Cai H,Peng B, [State-of-the-Art and Development Trends of Minimally Invasive Pancreatic Surgery]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition. 2020 Jul; [PubMed PMID: 32691547]|
|||Bai XL,Li X,Liang TB, [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2020 Jul 1; [PubMed PMID: 32610415]|
|||Evans DB, The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505. Annals of surgery. 2020 Jul 9; [PubMed PMID: 32657915]|
|||Klaiber U,Hackert T,Neoptolemos JP, Adjuvant treatment for pancreatic cancer. Translational gastroenterology and hepatology. 2019; [PubMed PMID: 31143848]|
|||Van Cutsem E,Tempero MA,Sigal D,Oh DY,Fazio N,Macarulla T,Hitre E,Hammel P,Hendifar AE,Bates SE,Li CP,Hingorani SR,de la Fouchardiere C,Kasi A,Heinemann V,Maraveyas A,Bahary N,Layos L,Sahai V,Zheng L,Lacy J,Park JO,Portales F,Oberstein P,Wu W,Chondros D,Bullock AJ, Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jul 24; [PubMed PMID: 32706635]|
|||Pokrzywa CJ,Abbott DE,Matkowskyj KA,Ronnekleiv-Kelly SM,Winslow ER,Weber SM,Fisher AV, Natural History and Treatment Trends in Pancreatic Cancer Subtypes. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract. 2019 Jan 31; [PubMed PMID: 30706376]|